Insider transaction filing: V — Vivos Therapeutics, Inc.
Why now
Thesis: Form 4 for small-cap Vivos lacks transaction detail in supplied text.
Catalyst to watch: Full filing with transaction specifics.
Main risk: Insider selling could pressure small-cap shares.
Why it matters
Form 4 insider filing for a small-cap issuer lacks transaction detail in the supplied text.
Details
Vivos Therapeutics, Inc. filed SEC Form 4 on 2026-09-18.